Hormone therapy and breast cancer;Hormonothérapie des cancers du sein

Bulletin du Cancer

Volumn 98, Issue 11, 2011, Pages 1311-1319

  De Cremoux, Patricia ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Antiestrogens; Aromatase inhibitors; Breast cancers; Hormone therapy

Indexed keywords

ANDROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; ESTROGEN SYNTHESIS; HUMAN; POSTMENOPAUSE; RECEPTOR DOWN REGULATION; REVIEW;

EID: 82455184275     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1466     Document Type: Review

References (55)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90 : 1371-88. (Pubitemid 28439961)
2. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001; 93 : 1449-57. (Pubitemid 32982673)
3. Jordan VC. Is tamoxifen the Rosetta stone for breast cancer? J Natl Cancer Inst 2003; 95 : 338-40. (Pubitemid 36395247)
4. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004; 5 : 207-13. (Pubitemid 38402112)
5. Green S, Chambon P. A superfamily of potentially oncogenic hormone receptors. Nature 1986; 324 : 615-7. (Pubitemid 17206346)
6. Lippman M, Bolan G, Huff K. Interactions of antiestrogens with human breast cancer in long-term tissue culture. Cancer Treat Rep 1976; 60 : 1421-9. (Pubitemid 8055854)
7. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93 : 5925-30. (Pubitemid 26190778)
8. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem 1997; 272 : 25832-8. (Pubitemid 27438906)
9. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392 : 49-53. (Pubitemid 26268330)
10. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82 : 4258-65. (Pubitemid 27525550)
11. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994; 31 : 41-52. (Pubitemid 24264211)
12. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389 : 753-8. (Pubitemid 27458965)
13. Kumar V, Chambon P. The estrogen receptor binds rightly to its responsive element as a ligand-induced homodimer. Cell 1988; 55 : 145-56.
14. Onata S, Tsai J, Tsai M, O'Malley B. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270 : 1354-7.
15. Cavailes V, Dauvois S, Danielau P, Parker M. Interactions of proteins with ranscriptionally active estrogen receptors. Proc Natl Acacd Sci U S A 1996; 93 : 11540-5.
16. Maruyama S, Fujimoto N, Asano K, Ito A. Suppression by estrogen receptor beta of AP-1 mediated transactivation through estrogen receptor alpha. J Steroid Biochem Mol Biol 2001; 78 : 177-84. (Pubitemid 32879333)
17. Watanabe T, Inoue S, Ogawa S, et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 1997; 236 : 140-5. (Pubitemid 27341854)
18. Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62 : 405-9. (Pubitemid 20292836)
19. Wakeling AE. Mechanisms of growth regulation of human breast cancer. Clin Endocrinol Metab 1990; 4 : 51-66. (Pubitemid 20163880)
20. Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L, Coombes RC. Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res 1991; 51 : 4685-92.
21. Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1994; 31 : 95-105. (Pubitemid 24264216)
22. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991; 83 : 1488-91.
23. Gylling H, Pyrhonen S, Mantyla E, Maenpaa H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 1995; 13 : 2900-5.
24. Fornander T, Rutqvist LE, Sjoberg HE, Blomqvist L, Mattsson A, Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990; 8 : 1019-24. (Pubitemid 20200189)
25. Mc McKeage K, Curran MP, Plosker GL. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs 2004; 64 : 633-48. (Pubitemid 38482444)
26. Jones SE. A new estrogen receptor antagonist - an overview of available data. Breast Cancer Res Treat 2002 ; 75(Suppl 1) : S19-21 (discussion S33-5).
27. Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptorpositive advanced breast cancer. Cancer Invest 2005; 23 : 173-81. (Pubitemid 40463915)
28. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 1990; 87 : 6883-7.
29. Miller WR, O'Neill J. Mammary steroidogenesis: therapeutic implications. Int J Rad Appl Instrum 1987; 14 : 369-75. (Pubitemid 17114227)
30. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985; 45 : 2900-6. (Pubitemid 15232767)
31. James VH, Reed MJ, Lai LC, et al. Regulation of estrogen concentrations in human breast tissues. Ann N Y Acad Sci 1990; 595 : 227-35. (Pubitemid 20282953)
32. Malet C, Vacca A, Kuttenn F, Mauvais-Jarvis P. 17 beta-estradiol dehydrogenase (E2DH) activity in T47D cells. J Steroid Biochem Mol Biol 1991; 39 : 769-75.
33. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15 : 342-55. (Pubitemid 24180792)
34. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009; 457 : 219-23.
35. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005; 12 : 701-20. (Pubitemid 41815772)
36. Simpson ER, Clyne C, Rubin G, et al. Aromatase - a brief overview. Annu Rev Physiol 2002; 64 : 93-127. (Pubitemid 34259227)
37. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005; 26 : 331-45. (Pubitemid 40686647)
38. Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM, Telford J. Regulation of aromatase activity within the breast. J Steroid Biochem Mol Biol 1997; 61 : 193-202. (Pubitemid 27455678)
39. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestanemediated irreversible inhibition of human aromatase. Mol Endocrinol 2007; 21 : 401-14. (Pubitemid 46184893)
40. Sasano H, Nagura H, Harada N, Goukon Y, Kimura M. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 1994; 25 : 530-5. (Pubitemid 24173872)
41. Santen RJ, Martel J, Hoagland M, et al. Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994; 79 : 627-32. (Pubitemid 24256565)
42. Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE, Chen S. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 1992; 140 : 337-43.
43. Brodie AM, Lu Q, Long BJ, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001; 79 : 41-7. (Pubitemid 34158777)
44. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001; 94 : 685-9. (Pubitemid 33035688)
45. Soudon J. Comparison of in vitro exemestane activity versus other antiaromatase agents. Clin Breast Cancer 2000; 1(Suppl 1) : S68-73.
46. Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res 2006; 66 : 10281-6. (Pubitemid 44799745)
47. Kao YC, Okubo T, Sun XZ, Chen S. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. Anticancer Res 1999; 19 : 2049-56. (Pubitemid 29392769)
48. Chen S, Zhou D, Okubo T, Kao YC, Yang C. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999; 6 : 149-56. (Pubitemid 29260046)
49. Blackwell KL. Are all aromatase inhibitors alike?. Breast Cancer Res Treat 2008; 112(Suppl 1) : 35-43.
50. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003; 3 : 821-31. (Pubitemid 37376980)
51. Traina TA, Poggesi I, Robson M, et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 2008; 111 : 377-88.
52. Nicolas Diaz-Chico B, German Rodriguez F, Gonzalez A, et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007; 105 : 1-15.
53. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 : 747-52.
54. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101 : 736-50.
55. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22 : 1736-47.